<DOC>
	<DOC>NCT01485146</DOC>
	<brief_summary>This Phase 1, double-blind (sponsor open), placebo controlled study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of ETC-1002 in healthy subjects.</brief_summary>
	<brief_title>A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Major Healthy male and female subjects of nonchild bearing potential as determined by medical history, physical exam and vial sign measurements Body Mass Index of 1832 kg/m2 inclusive with body weight &gt;50 kg Major Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;1.2 x Upper Limit of Normal(ULN), serum creatinine &gt;ULN, Hemoglobin &lt;12.0 g/dL Clinically significant disease that requires a physician's care and/or would interfere with study evaluations History of drug or alcohol abuse, consumption of alcohol within 48 hours prior to randomization, or a positive test for alcohol or drugs with a high potential for abuse prior to randomization Use of any prescription or nonprescription drugs, vitamins, or dietary supplements within 14 days prior to randomization Other exclusion criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>